�QuatRx Pharmaceuticals, a
privately-held biopharmaceutical company focused on development and
commercialization of compounds to treat endocrine, metabolic and
cardiovascular disorders, announced that it has initiated a second
Phase 3 clinical trial of Ophena(TM) (ospemifene tablets), the company's
estrogen-free oral therapy in development for the treatment of vaginal
symptoms associated with menopause.
The study is the secondment pivotal Phase 3 clinical trial for Ophena(TM),
a new selective estrogen receptor modulator (SERM) for the treatment of
postmenopausal vaginal syndrome (PVS), a common condition in postmenopausal
women. PVS, also known as vaginal atrophy, is characterized by progressive
long-term vaginal symptoms such as dryness, irritation and sexual pain
(dyspareunia). The first Phase 3 test for Ophena(TM) met all the
co-primary endpoints at a 60 mg dose, with statistically significant
improvements in vaginal dryness and dyspareunia, as well as statistically
significant improvement in the proportion of parabasal and superficial
cells in the epithelial tissue of vaginal walls and a decline in vaginal pH
levels.
The randomised, double-blind study will seek to inscribe 750
postmenopausal women at more than 100 trial centers throughout the United
States. Women participating in the study will be treated with either a 60
mg once daily oral dose of Ophena(TM) or placebo over the 12-week discussion
period. All women will also be supplied with a non-hormonal vaginal
lube to be applied as needed during the discussion period.
The co-primary endpoints of the study ar the change from baseline to
week 12 in the percentage of parabasal cells in the vaginal maturation
forefinger, the part of trivial cells in the vaginal maturation index,
vaginal pH, and improvements in the most pesky moderate to severe
vulvovaginal atrophy symptoms of vaginal dryness and dyspareunia.
"We were very pleased with the results of the first Phase 3 run for
Ophena(TM) and believe this adjacent pivotal study will present another
important development milestone for QuatRx," said Robert L. Zerbe, M.D.,
headman executive officeholder and president of QuatRx. "For the large population
of postmenopausal women affected by progressive and vexatious vaginal
symptoms, and specially those implicated about the health risks associated
with long-term estrogen-based therapy, we believe Ophena(TM) has the
potential to be an important new treatment option."
About Postmenopausal Vaginal Syndrome
Postmenopausal vaginal syndrome (PVS) is a chronic and progressive
condition characterized by symptoms including vaginal dryness, sexual pain
(dyspareunia) and irritation. Declining oestrogen levels during menopause
can cause tissues of the vaginal lining to grow thinner and to misplace
elasticity, a condition known as withering. Dryness and irritation associated
with reductions in vaginal secretions much cause hurting or hemorrhage during
sexual intercourse. It is estimated that 45-75 percent of post-menopausal
women experience chronic symptoms of PVS. Current prescription treatments
approved for this condition all comprise estrogen, administered either
by word of mouth or locally in the vagina. SERMs that ar currently approved and
marketed in the United States have non been shown to get beneficial
personal effects on vaginal tissue and none ar approved for use in treating
symptoms of PVS.
About QuatRx
QuatRx Pharmaceuticals is focused on the discovery, licensing,
development and commercialization of compounds in the endocrine, metabolic
and cardiovascular therapeutic areas. In improver to Ophena(TM), QuatRx has
three other product candidates in alive clinical growth and an
advanced presymptomatic program. Fispemifene is a new selective estrogen
receptor antagonist that is in Phase 2 studies as an oral treatment for the
symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective
thyroidal receptor beta agonist, is in Phase 1 as a potential treatment for
dyslipidemia. Becocalcidiol, a novel Vitamin D analogue, is in Phase 2
clinical trials for the treatment of psoriasis through QuatRx's partner,
Galderma. QuatRx's preclinical program is designed to address sex steroid
pendant diseases through inhibition of 17beta-HSD enzymes. In Europe,
QuatRx operates through its Finnish subsidiary, Hormos Medical Ltd, situated
in Turku, Finland. For press releases and other Company entropy, please
chatter http://www.quatrx.com.
QuatRx Pharmaceuticals
http://www.quatrx.com
More info
Monday 8 September 2008
Wednesday 20 August 2008
Madonna celebrates 50th birthday
Madonna celebrates her fiftieth birthday today (August 16).
The singer is reportedly expected to agree a party at her home in Wiltshire later.
During her calling Madonna has sold around 120 gazillion albums and 40 trillion singles, according to Guinness World Records.
Earlier this year she scored her 13th Number One single in the UK singles chart with '4 Minutes'.
She has had more than 60 Top 10 UK singles and nine chart topping albums.
Her Number One hit 'Like A Prayer', which was released in 1989, has also topped a list of her ultimate tracks in a poll compiled by HMV, to keep her 50th birthday.
Aug 16, 2008 at BRADNINCH GUILDHALL, BRADNINCH ,DEVON -
Aug 16, 2008 at GATESHEAD INTERNATIONAL STADIUM, NEWCASTLE-UPON-TYNE -
Aug 16, 2008 at PONTARDAWE FESTIVAL, Pontardawe, Wales -
More info
The singer is reportedly expected to agree a party at her home in Wiltshire later.
During her calling Madonna has sold around 120 gazillion albums and 40 trillion singles, according to Guinness World Records.
Earlier this year she scored her 13th Number One single in the UK singles chart with '4 Minutes'.
She has had more than 60 Top 10 UK singles and nine chart topping albums.
Her Number One hit 'Like A Prayer', which was released in 1989, has also topped a list of her ultimate tracks in a poll compiled by HMV, to keep her 50th birthday.
Aug 16, 2008 at BRADNINCH GUILDHALL, BRADNINCH ,DEVON -
Aug 16, 2008 at GATESHEAD INTERNATIONAL STADIUM, NEWCASTLE-UPON-TYNE -
Aug 16, 2008 at PONTARDAWE FESTIVAL, Pontardawe, Wales -
More tickets
More info
Sunday 10 August 2008
The Prostate Cancer Charity Comments On Reports That The Duke Of Edinburgh Has Been Diagnosed With Prostate Cancer, UK
�The Prostate Cancer Charity comments on reports that The Duke of Edinburgh has been diagnosed with prostate cancer.
John Neate, Chief Executive of The Prostate Cancer Charity, aforementioned: "It is obviously a potentially unmanageable time when any diagnosing of prostate gland cancer is made. If indeed, as reports suggest, The Duke of Edinburgh has been diagnosed with prostate genus Cancer, on behalf of The Prostate Cancer Charity, I would care to bid him and his menage the best through what may be an uncertain time.
"Every year in the UK more than 7,000 men ar diagnosed with prostate cancer in their 80's. Unlike many early cancers, prostate gland cancer is different in that, in some cases it will not movement any problems in a man's life. Prostate crab is the most unremarkably diagnosed genus Cancer in manpower in the UK and all manpower need to increase their awareness of the disease.
"There are a number of ways to deal prostate cancer dependent on the stage in development it has reached. It is essential that all men with prostate cancer have access to high quality information and to a specializer nurse wHO can serve them sail the a great deal complex choices about treatment options and support them through their chosen treatment route."
Prostate cancer is the nearly common genus Cancer diagnosed in men in the UK. Every year in the UK 35,000 workforce are diagnosed with prostate cancer. One man dies every hour of prostate gland cancer in the UK.
African Caribbean men ar three times more potential to develop prostate crab than white men.
The Prostate Cancer Charity is striving for a world where lives are no longer limited by prostate cancer. The Charity is fighting prostate cancer on every front - through research, support, information and campaigning.
If you have any queries about prostate cancer call The Prostate Cancer Charity's confidential helpline 0800 074 8383 which is staffed by specialist nurses and open from 10am to 4pm Monday to Friday and Wednesdays from 7 - 9pm or impose http://www.prostate-cancer.org.uk
The Prostate Cancer Charity
More info
John Neate, Chief Executive of The Prostate Cancer Charity, aforementioned: "It is obviously a potentially unmanageable time when any diagnosing of prostate gland cancer is made. If indeed, as reports suggest, The Duke of Edinburgh has been diagnosed with prostate genus Cancer, on behalf of The Prostate Cancer Charity, I would care to bid him and his menage the best through what may be an uncertain time.
"Every year in the UK more than 7,000 men ar diagnosed with prostate cancer in their 80's. Unlike many early cancers, prostate gland cancer is different in that, in some cases it will not movement any problems in a man's life. Prostate crab is the most unremarkably diagnosed genus Cancer in manpower in the UK and all manpower need to increase their awareness of the disease.
"There are a number of ways to deal prostate cancer dependent on the stage in development it has reached. It is essential that all men with prostate cancer have access to high quality information and to a specializer nurse wHO can serve them sail the a great deal complex choices about treatment options and support them through their chosen treatment route."
Prostate cancer is the nearly common genus Cancer diagnosed in men in the UK. Every year in the UK 35,000 workforce are diagnosed with prostate cancer. One man dies every hour of prostate gland cancer in the UK.
African Caribbean men ar three times more potential to develop prostate crab than white men.
The Prostate Cancer Charity is striving for a world where lives are no longer limited by prostate cancer. The Charity is fighting prostate cancer on every front - through research, support, information and campaigning.
If you have any queries about prostate cancer call The Prostate Cancer Charity's confidential helpline 0800 074 8383 which is staffed by specialist nurses and open from 10am to 4pm Monday to Friday and Wednesdays from 7 - 9pm or impose http://www.prostate-cancer.org.uk
The Prostate Cancer Charity
More info
Tuesday 1 July 2008
Coldplay album debuts at No. 1
Rock band Coldplay�s new album debuted at No. 1 on the U.S. pop music chart Tuesday, largely bucking the sales slides that have affected other musicians, Reuters reports the group�s label as saying.
Viva La Vida or Death and All His Friends, Coldplay�s fourth release, sold more than 720,000 copies in the six days ended Sunday, Capitol Records said.
See Also
Wednesday 18 June 2008
Monday 2 June 2008
Doshermanos
Artist: Doshermanos
Genre(s):
Other
Discography:
Lo Llevo Dentro
Year: 2004
Tracks: 4
Times New Viking, No Age, Jay Reatard Keep Lo-Fi Punk Alive
Tuesday 27 May 2008
Superheroes go back to work
Comic-book-hero movie company Marvel Studios has reached an interim agreement with the Writers Guild of America, enabling striking Hollywood writers to go back to work on their projects.
For Marvel, it means that work can resume on 'Ant Man', 'Captain America', 'Thor' and 'The Avengers'.
'Hulk' and 'Iron Man' were already in production and were not affected by the strike; they are set for release later this year.
Film and television studio Lionsgate, Hollywood's biggest indie producers, has also reached an interim agreement with the guild.
Upcoming Lionsgate films include 'Rambo', 'The Eye' and 'Saw 5', while its television series include 'Weeds', 'Mad Men' and a new show, 'Fear Itself'.
"The writers' issue seems on its way to being solved, and Lionsgate felt it was an important time, particularly in view of our TV series, to have our writer partners get back to work," Lionsgate said in a statement.
"We look forward to a broad industry agreement soon," said a company representative.
Writers already have reached interim deals with studios including United Artists, the film production house backed by Tom Cruise and The Weinstein Co, run by media-mogul brothers Harvey and Bob Weinstein.
Writers and producers resumed talks this week, aimed at ending a nearly three-month strike that has stopped most prime-time television production and some hope smaller deals will put pressure on the big studios.
For Marvel, it means that work can resume on 'Ant Man', 'Captain America', 'Thor' and 'The Avengers'.
'Hulk' and 'Iron Man' were already in production and were not affected by the strike; they are set for release later this year.
Film and television studio Lionsgate, Hollywood's biggest indie producers, has also reached an interim agreement with the guild.
Upcoming Lionsgate films include 'Rambo', 'The Eye' and 'Saw 5', while its television series include 'Weeds', 'Mad Men' and a new show, 'Fear Itself'.
"The writers' issue seems on its way to being solved, and Lionsgate felt it was an important time, particularly in view of our TV series, to have our writer partners get back to work," Lionsgate said in a statement.
"We look forward to a broad industry agreement soon," said a company representative.
Writers already have reached interim deals with studios including United Artists, the film production house backed by Tom Cruise and The Weinstein Co, run by media-mogul brothers Harvey and Bob Weinstein.
Writers and producers resumed talks this week, aimed at ending a nearly three-month strike that has stopped most prime-time television production and some hope smaller deals will put pressure on the big studios.
Subscribe to:
Posts (Atom)